Skip to main content
SpringerLink
Log in

Editor’s Commentary: A Vision for the Journal’s Continued Growth

  • Commentary
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Donawa ME. The evolving process of European combination product review, part II. Med Device Technol. 2008;19:26. 28–31.

    Google Scholar 

  2. Donawa M. US regulation of combination products. Med Device Technol. 2009;20:22–25.

    PubMed  Google Scholar 

  3. Van Herendael H, Pinter A, Ahmad K, et al. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. Europace. 2010;12:618–625.

    Article  Google Scholar 

  4. Benezet J. Diaz de la Llera LS, Cubero JM, et al. Drug-eluting stents following rotational atherectomy for heavily calcified coronary lesions: long-term clinical outcomes. J Invasive Cardiol. 2011; 23:28–32.

    PubMed  Google Scholar 

  5. Rodriguez MA, Helms E, Shubert J, Pavri BB. Pacemaker malfunction induced by a pharmaco-metabolic “perfect storm”: a brief report. J Clin Pharmacol. 2011;51:107–109.

    Article  Google Scholar 

  6. Landais P, Méresse V, Ghislain JC. Evaluation and validation of diagnostic tests for guiding therapeutic decisions. Therapic. 2009;64:187–201.

    Article  Google Scholar 

  7. Becker R Jr. Mansfield E. Companion diagnostics. Clin Adv Hematol Oncol. 2010;8:478–479.

    PubMed  Google Scholar 

  8. Mallal S. Phillips E, Carosi G, et al. for the PREDICT-1 Study Team. HLA-B•5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568–579.

    Article  Google Scholar 

  9. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med. 2008;358:637–639.

    Article  CAS  Google Scholar 

  10. Institute of Medicine. To Err Is Human: Building a Safer Health System. Washington. DC: National Academics Press: 2000.

    Google Scholar 

  11. Graybeal C, Long R, Scalise-Smith D, Zeibig E. The art and science of interprofessional education. J Allied Health. 2010;39(3 Pt 2):232–237.

    PubMed  Google Scholar 

  12. Turner JR. New Drug Development: An Introduction to Clinical Trials. 2nd ed. New York: Springer 2010.

    Book  Google Scholar 

  13. FDA. Strategic priorities 2011–2015: responding to the public health challenges of the 21st century (draft), http://www.fda.gov/downloads/AboutFDAReportsManualsForms/Reports/StrategicActionPlan/UCM226907.pdf (accessed January 5, 2011).

  14. International Council of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. www.icmje.org (accessed January 5, 2011).

  15. International Council of Medical Journal Editors. Toward more uniform conflict disclosures: the updated ICMJE conflict of interest reporting form, http://www.icmje.org/updated_coi.pdf (accessed January 5, 2011).

  16. Council of Science Editors. Promoting integrity in scientific journal publications. 2009. http://www.councilscienceeditors.org/files/public/entire_whitepaper.pdf (accessed January 5, 2011).

  17. World Association of Medical Editors. http://www.wame.org (accessed January 5, 2011).

Download references

Authors
  1. J. Rick Turner PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turner, J.R. Editor’s Commentary: A Vision for the Journal’s Continued Growth. Ther Innov Regul Sci 45, 113–117 (2011). https://doi.org/10.1177/009286151104500202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/009286151104500202

Search

Navigation